Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Novartis
Novartis
Kivu Bioscience Inc.
Hoffmann-La Roche
Endeavor Biomedicines, Inc.
City of Hope Medical Center
Aveni Foundation
M.D. Anderson Cancer Center
University of California, Irvine
M.D. Anderson Cancer Center
ViroMissile, Inc.
AstraZeneca
Washington University School of Medicine
Essen Biotech
MacroGenics
Alliance for Clinical Trials in Oncology
City of Hope Medical Center
University of Nebraska
Adela, Inc
Perspective Therapeutics
M.D. Anderson Cancer Center
Ocellaris Pharma, Inc.
Eli Lilly and Company
Var2 Pharmaceuticals
UNICANCER
Memorial Sloan Kettering Cancer Center
Tanabe Pharma America, Inc.
Transgene
HiFiBiO Therapeutics
TScan Therapeutics, Inc.
Tango Therapeutics, Inc.
Bayer
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Actym Therapeutics, Inc.
Hadassah Medical Organization
British Columbia Cancer Agency
Washington University School of Medicine
Valo Therapeutics Oy
Epkin
Guangzhou FineImmune Biotechnology Co., LTD.
Institut Bergonié
GONGCHU Biotechnology Co., Ltd
Jonsson Comprehensive Cancer Center
Washington University School of Medicine
Turning Point Therapeutics, Inc.
University of Pittsburgh
Telix Pharmaceuticals (Innovations) Pty Limited
PharmaMar
Institut Bergonié
University of California, Irvine